29668-43-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2,3-Dihydro-1,4-benzodioxine-5-carbaldehyde is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Perfumery and Flavoring Industry:
In the perfumery and flavoring industry, 2,3-Dihydro-1,4-benzodioxine-5-carbaldehyde is used as a fragrance ingredient and flavoring agent for its distinct floral, sweet, and powdery scent and taste. It contributes to the creation of a wide range of perfumes, colognes, and flavorings, enhancing their overall appeal and sensory experience.
Used in Agrochemicals:
2,3-Dihydro-1,4-benzodioxine-5-carbaldehyde also finds applications in the agrochemical industry, where it is utilized as a precursor for the synthesis of various agrochemical products. Its potential use in this field highlights its versatility and importance in different sectors.
Used as a Precursor in Organic Synthesis:
As a precursor in organic synthesis, 2,3-Dihydro-1,4-benzodioxine-5-carbaldehyde is employed in the production of other organic compounds. Its ability to undergo various chemical reactions makes it a valuable starting material for the synthesis of a diverse range of organic molecules, further expanding its applications in research and industry.

InChI:InChI=1/C9H8O3/c10-6-7-2-1-3-8-9(7)12-5-4-11-8/h1-3,6H,4-5H2

Upstream product

• 624-73-7 1,2-Diiodoethane 
• 24677-78-9 2,3-dihydroxybenzaldehyde 
• 106-93-4 ethylene dibromide 
• 274910-19-9 (2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methanol 

Downstream Products

• 274910-19-9 (2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methanol 
• 860653-20-9 [2-(allylamino)-5-chlorophenyl](2,3-dihydro-1,4-benzodioxin-5-yl)methanol 
• 880782-74-1 (2,3-dihydro-benzo[1,4]dioxin-5-yl)-(1-trityl-1H-imidazol-4-yl)-methanol 
• 201221-22-9 {5-chloro-2-[(2,2-dimethylpropyl)amino]phenyl}-(2,3-dihydro-1,4-benzodioxin-5-yl)methanol 
• 1292850-59-9 N-{4-chloro-2-[2,3-dihydro-1,4-benzodioxin-5-yl-(hydroxy)methyl]phenyl}-2,2-dimethylpropanamide 
• 1312470-11-3 C₂₁H₁₉NO₃ 
• 1311515-42-0 C₁₇H₂₁NO₆ 
• 19815-97-5 2-bromo-1-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)ethanone 
• 274910-20-2 2-(2,3-dihydro-1,4-benzodioxin-5-yl)acetic acid 
• 116939-11-8 monochlormethylbenzo-1,4-dioxane 
• 158504-37-1 methyl 8-amino-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxylate 
• 214894-91-4 2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid methyl ester 
• 4442-53-9 2,3-dihydro-1,4-benzodioxine-5-carboxylic acid 

Relevant academic research and scientific papers

2-phenylcyclopropyl methylamine derivative, and preparation method and application thereof

The invention discloses a 2-phenylcyclopropyl methylamine derivative, and a preparation method and application thereof. The 2-phenylcyclopropyl methylamine derivative provided by the invention has a structure as shown in the following formula I, has affinity activity to a dopamine receptor and/or a 5-hydroxytryptamine receptor, and can be used for treating mental diseases.

2-Phenylcyclopropylmethylamine Derivatives as Dopamine D2Receptor Partial Agonists: Design, Synthesis, and Biological Evaluation

Partial agonist activity at the dopamine D2 receptor (D2R) is the primary pharmacological feature of the third-generation antipsychotics─aripiprazole, brexpiprazole, and cariprazine. However, all these drugs share a common phenyl-piperazine moiety as the primary pharmacophore. In this study, we designed and synthesized a series of novel compounds based on the 2-phenylcyclopropylmethylamine (PCPMA) scaffold and studied their pharmacological activity at the D2R. A number of potent D2R partial agonists were identified through binding affinity screening and functional activity profiling in both G protein and β-arrestin assays. The structure-functional activity relationship results showed that the spacer group is crucial for fine-tuning the intrinsic activity of these compounds. Compounds (+)-14j and (+)-14l showed good pharmacokinetic properties and an unexpected selectivity against the serotonin 2A (5-HT2A) receptor. Preliminary suppressive effects in a mouse hyperlocomotion model proved that these PCPMA-derived D2R partial agonists are effective as potential novel antipsychotics.

3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

PYRANOQUINAZOLINE DERIVATIVES AND NAPHTHOPYRAN DERIVATIVES

[Problem] A problem is presented in that conventional photochromic compounds cannot be considered adequate in terms of the colorizing/decolorizing rate and durability, and the production process therefore has many steps. The present invention provides an industrially applicable photochromic compound that has both a rapid colorizing/decolorizing reaction and high durability and can also be synthesized at a low cost. [Solution] This compound is characterized in that etheric oxygen atoms are bonded to the carbon atoms at position 1 of a pyranoquinazoline (8H-pyrano[3,2-f]quinazoline) skeleton and position 10 of a naphthopyran (3H-naphtho[2,1-b]pyran) skeleton, said compound having photochromic properties and being a photochromic compound that has both a rapid colorizing/decolorizing reaction and high durability. Also provided is an industrially applicable photochromic compound that can be synthesized at a low cost.

Heterocyclic compound

The present invention relates to compound (I) or a salt thereof which has a ROR γ t inhibitory action. wherein each symbol is as defined in the specification.

GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS

The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as m PGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

Synthesis and properties of bimetallic Hoveyda-Grubbs metathesis catalysts

The catalytic activity of ruthenium Hoveyda-Grubbs complexes in olefin metathesis is a function of complex steric and electronic effects acting on initiation and propagation steps. In order to study the π-electron factors influencing the initiation process, we attempted syntheses of bimetallic complexes with common organic ligands bearing two chelate rings. While most of the studied ligand exchange reactions of the isomeric bis-chelating benzene derivatives gave mixtures of unstable complexes, a homodinuclear derivative of 1,4-dimethoxy-2,5-divinylbenzene was sparingly soluble and precipitated from the reaction mixture in a pure form. The complex was studied with spectroscopic and X-ray methods, which confirmed the symmetrical bimetallic structure. However, in model metathesis reactions the catalyst displayed activity very comparable to the related monometallic complexes. This suggests that in the bimetallic system two consecutive initiation processes of the metathesis catalyst (first, bimetallic complex + olefin → monometallic complex + propagating species; second, monometallic complex + olefin → styrene + propagating species) proceed at similar rates and, thus, no cooperativity between the two steps is displayed. Properties of the family of bimetallic complexes were probed with NMR studies, and π-electronic effects operating in the systems were discussed.

Discovery of novel tricyclic compounds as squalene synthase inhibitors

In the present article, we have reported the design, synthesis, and identification of highly potent benzhydrol derivatives as squalene synthase inhibitors (compound 1). Unfortunately, the in vivo efficacies of the compounds were not enough for acquiring the clinical candidate. We continued our investigation to obtain a more in vivo efficacious template than the benzhydrol template. In our effort, we focused on a benzoxazepine ring and designed a new tricyclic scaffold by the incorporation of heterocycle into it. Prepared pyrrolobenzoxazepine derivatives showed further efficient in vitro and in vivo activities.

TRICYCLIC COMPOUND

The present invention relates to tricyclic compounds each represented by the following formula (I): (wherein, R1, R2, R2', R3, R4, X, Y and Z have the same meanings as defined in the specification); and a drug containing the compound. Since the compounds according to the present invention exhibit an excellent squalene synthetase inhibitory effect and cholesterol synthesis inhibitory effect so that they are useful as a drug such as preventive and/or remedy for diseases in mammals including humans such as hyperlipemia, e.g., hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterolemia and/or arteriosclerosis.